Comet Therapeutics Earns $28.5 Million Series A with Sight Set on Metabolic Diseases

ALEX KEOWN | June 19, 2019

article image
With $28.5 million in financing, Cambridge, Mass.-based Comet Therapeutics is emerging from stealth mode with a focus on developing a portfolio of drug candidates that centers around efforts to re-engineer CoEnzyme-A (CoA). Comet’s CoA platform has numerous potential applications including metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. In an interview with BioSpace, David de Graaf, president and chief executive officer of Comet Therapeutics, said that although the role of CoA in the body has been understood for a long time, no one had really thought to apply that knowledge in a pharmaceutical manner. CoA is known for its role in helping enzymes in the body do the job they were designed to do, including the building of and breaking down of proteins, as well as mitochondrial health and the proper functioning of the TCA cycle, which provides the energy cells need to live.

Spotlight

Premas Biotech

Premas Biotech is a specialized protein services company offering services in cloning, expression, scale up & process development, and customized assay development. We are ISO9001:2008 company and cGMP compliant. We have done over 400 proteins in past 4.5 years.

OTHER ARTICLES

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

Premas Biotech

Premas Biotech is a specialized protein services company offering services in cloning, expression, scale up & process development, and customized assay development. We are ISO9001:2008 company and cGMP compliant. We have done over 400 proteins in past 4.5 years.

Events